Comparing the current results to its competitors, Galapagos Nv reported Revenue increase in the 4 quarter 2025 by 303.5 % year on year. The sales growth was above Galapagos Nv's competitors' average revenue growth of 10.43 %, achieved in the same quarter.
Galapagos Nv's Comment on Competition and Industry Peers
The company is exiting the cell therapy business to focus on new business development opportunities, with a priority on oncology and immunology and inflammation (I&I), while remaining open to other fields. It maintains a longstanding partnership with Gilead, which provides a strategic advantage globally. The competitive landscape includes risks related to patent protection and the potential for competitors to independently develop similar drugs or technologies. Competitors include Pfizer, with siltuximab (anti-IL-6); AstraZeneca, with anifrolumab (Saphnelo®, anti-IFN); and Argenx, with efartigimod (Vyvgart®, anti-FcRn), which may launch before the end of the decade. Many competitors possess significantly greater financial, technical, and human resources. Additionally, industry consolidation through mergers and acquisitions may increase competition.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.
Edesa Biotech Inc's business model focuses on the development and commercialization of innovative therapeutics in the field of dermatology and gastrointestinal diseases.
Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.
Sources:
Galapagos Nv’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Galapagos Nv versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
